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Abstract
Background: Suboptimal translation of valid and relevant information in clinical practice is a problem for all health
systems. Lack of information independent from commercial influences, limited efforts to actively implement evidence-
based information and its limited comprehensibility are important determinants of this gap and may influence an excessive
variability in physicians' prescriptions. This is quite noticeable in Italy, where the philosophy and methods of Evidence-
Based Medicine still enjoy limited diffusion among practitioners. Academic detailing and pharmacist outreach visits are
interventions of proven efficacy to make independent and evidence-based information available to physicians; this
approach and its feasibility have not yet been tested on a large scale and, moreover, they have never been formally tested
in Italy.
Methods/Design: Two RCTs are planned:
1) a two-arm cluster RCT, carried out in Emilia-Romagna and Friuli Venezia Giulia, will evaluate the effectiveness of small
group meetings, randomising about 150 Primary Care Groups (corresponding to about 2000 GPs) to pharmacist
outreach visits on two different topics. Physicians' prescriptions (expressed as DDD per 1000 inhabitants/day),
knowledge and attitudes (evaluated through the answers to a specific questionnaire) will be compared for target drugs
in the two groups (receiving/not receiving each topic).
2) A three-arm RCT, carried out in Sardinia, will evaluate both the effectiveness of one-to-one meetings (one pharmacist
visiting one physician per time) and of a 'new' information format (compared to information already available) on changing
physicians' prescription of specific drugs. About 900 single GPs will be randomised into three groups: physicians receiving
a visit supported by "traditional" information material, those receiving a visit with "new" information material on the same
topic and those not receiving any visit/material.
Discussion: The two proposed RCTs aim to evaluate the organisational feasibility and barriers to the implementation
of independent information programs led by NHS pharmacists. The objective to assess a 10 or 15% decreases in the
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prescription of the targeted drugs is quite ambitious in such 'natural' settings, which will be minimally altered by the
interventions themselves; this in spite of the quite large sample sizes used comparing to other studies of these kind.
Complex interventions like these are not easy to evaluate, given the many different variables into play. Anyway, the
pragmatic nature of the two RCTs appears to be also one of their major strengths, helping to provide a deeper insight
on what is possible to achieve – in terms of independent information – in a National Health System, with special reference
to Italy.
Trial registration: ISRCTN05866587 (cluster RCT) and ISRCTN28525676 (single GPs RCT)
Background
Information that doctors receive on benefits and risks of
currently used drug treatments generally comes, either
directly or indirectly, from the pharmaceutical industry
[1-3]. It may thus be unsystematic and biased [4], and
may be a component of the (often observed) excessive
variability in physicians' prescriptions [5,6], uneasy to
explain if one merely looks at evidence-based findings in
medical literature.
In recent years the Italian Ministry of Health has made
efforts in expanding physicians' access to independent
and evidence-based information, like freely distributing
the Italian translation of Clinical Evidence and enhancing
the quality of the already freely distributed NHS Drug
Information Bulletin. Nonetheless, sub-optimal diffusion
of independent scientific information is apparent, as well
as its comprehensibility to physicians who do not gener-
ally have epidemiology and statistics in their medical
school background [7-11]. Improving access to, as well as
comprehensibility of, evidence-based information remain
important goals for Health Authorities, both at national
and local levels.
However, simple diffusion of information – even if "evi-
dence-based" – does not seem to affect prescribing behav-
iour, whereas active interventions like educational
outreach visits to doctors (either one to one or small
groups meetings), often employing pharmacists, seem
more effective especially when clinical information is sup-
plemented by prescribing data, according to an "audit &
feedback" method [12-16].
Hence, in Italy there is room for improving independent
information initiatives, promoting an active outreach sys-
tem and a different role for NHS pharmacists, the latter
being too often confined in administrative/auditing roles.
There is also room for improving comprehensibility of
medical information, which is infrequently targeted to
"average" doctors and hardly ever offered in a clear, direct
and appealing fashion, looking at the context of clinical
practice [17].
The available evidence on the effectiveness of outreach
visits comes from the English speaking world (United
Kingdom, Canada, Australia, United States), whereas no
studies have formally evaluated their effectiveness, feasi-
bility and perceived usefulness in Italy [12-14]. For this
reason, two pragmatic randomised controlled trials
(RCTs) are proposed to carry out this complex evaluation
in different settings: the first one, carried out in Emilia-
Romagna and Friuli Venezia Giulia, will be a cluster RCT
evaluating whether information meetings led by pharma-
cists with small groups of physicians change their pre-
scribing behaviour, attitude and knowledge (being a
cluster design the most appropriate to address the issue of
contamination between groups); whereas the second one,
carried out in Sardinia, will be a RCT evaluating one to
one visits and the added value of a new format in improv-
ing doctors' knowledge, attitudes and prescribing practice
[17].
Two more reasons to carry out these studies are that they
would represent an unprecedented effort to accomplish
such evaluation on quite a large scale, considering that
three Italian regions would participate (Emilia Romagna
with about 1500 physicians, assisting a population of
about 2 million inhabitants; Friuli Venezia Giulia with
about 400 physicians, assisting a population of about
400,000; and Sardinia with about 900 physicians, assist-
ing a population of about 1 million) and that these inter-
ventions would be carried out in a 'natural' organizational
setting, which would be minimally altered by the inter-
ventions themselves.
Objectives
Overall, the two studies will specifically evaluate:
￿ whether information meetings with small groups of
physicians (in Emilia-Romagna and Friuli Venezia Giulia)
or with single physicians (in Sardinia), led by pharmacists
and organised by Local Health Authorities within a large
scale independent information program involving all
local GPs, is organisationally feasible (and how barriers
can be reduced)
￿ whether such programs can be effective in changing phy-
sicians' prescribing behaviourBMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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￿ whether the provided information can also modify
knowledge and attitudes of physicians on benefits and
risks of the drugs under scrutiny (in Emilia-Romagna and
Friuli Venezia Giulia)
￿ whether the format of information can affect the out-
comes, specifically: whether an "enriched" format tar-
geted at the average GP can improve knowledge, attitudes
and prescribing behaviour more than a "traditional" for-
mat (in Sardinia)
￿ whether an active role of a GP (delegate by the PCG) in
information meetings is feasible and useful (in Emilia-
Romagna and Friuli Venezia Giulia)
Methods/Design
Study population
Emilia-Romagna and Friuli Venezia Giulia study (cluster RCT)
Primary Care Groups (PCGs) will be the unit of randomi-
sation (cluster). PCGs are defined as small groups, rang-
ing from about 10 to 20 general practitioners (GPs) and
assisting about 8,000 to 25,000 people in a defined area.
A general rule is to include PCGs with less than or equal
to 20 GPs. Exceptions may be accepted (considering the
pragmatic nature of the study) but should be adequately
justified by Local Health Authorities recruiting them. In
any case, the proposal to split groups with more than 20
subjects will be made.
Local Health Authorities, which are in charge of the local
organization of the study, should actively promote the
information meetings by making them part of compul-
sory education and/or providing CME credits.
Sardinia study (randomising single GPs)
Single GPs will be the unit of randomisation. All GPs are
eligible, provided that their Local Health Authority has an
organised system for tracking their prescriptions made
within the NHS till the 5th ATC level, in order to evaluate
these prescriptions and to provide doctors with feedback.
As in the first study, Local Health Authorities should
actively promote the outreach visits among single GPs.
Intervention/Exposure
Emilia-Romagna and Friuli Venezia Giulia study (cluster RCT)
A cluster RCT will be performed. PCGs will participate to
two rounds of small group information meetings where a
trained pharmacist, possibly supported by a GP (a "refer-
ent", delegate by the PCG), will provide information, dis-
cussing the contents of a bulletin specifically developed
about the main studies/literature available on benefits
and risks of drugs for preventing and/or curing a specific
disease (enriched format) [17].
Within each round of visits (taking place in spring and
autumn of 2007, respectively), PCGs will be randomised
in two groups: those receiving information about a spe-
cific topic and those not receiving it (Fig. 1). To improve
acceptability to Local Health Authorities and sample effi-
ciency, PCGs not receiving information about one specific
topic (e.g. topic A) will receive another topic (e.g. topic B).
Two evaluations will then be carried out: for topic A
related outcomes, recipients vs non recipients of topic A
will be compared; conversely, for topic B related out-
comes, the comparison will be between recipients vs non
recipients of topic B.
Considering two rounds of information meetings, four
topics will be needed (two topics each round) and four
interventions will be tested overall. While these are differ-
Design of the cluster study (Emilia-Romagna and Friuli Venezia Giulia): effectiveness of information meetings Figure 1
Design of the cluster study (Emilia-Romagna and Friuli Venezia Giulia): effectiveness of information meetings.
About
150 Primary Care Groups
Topic A (75) Topic B (75)
Main comparisons: 
• topic A vs no topic A
• topic B vs no topic BBMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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ent specific comparisons, the same general hypothesis will
be tested: whether information meetings led by pharma-
cists are effective in changing physicians' behaviour (com-
paring to no visit on the same topic). The reasons why
four comparisons are planned are to better evaluate the
feasibility of this kind of intervention (which could be
eventually proposed in the Italian NHS on a routine basis)
and to have better insight into its effectiveness, since this
may depend on the kind of topics and on the extent of
information presented.
The first couple of topics chosen (for the spring 2007
round) are: 'drugs for the treatment of benign prostatic
hyperplasia', and 'drugs for the primary prevention of
osteoporotic fractures in elderly people'. The second cou-
ple of topics will be chosen about two-three months
before the autumn 2007 round and this choice will
depend, as well as for the first two topics, on relevance for
clinical practice, limited availability and diffusion of
information independent from drug industry, possibility
to synthesize clear and evidence-based messages on bene-
fits and risks of therapies and possibility to affect drug pre-
scriptions significantly.
Stratified randomisation will be carried out within each
Local Health Authority (LHA), using the number of
assisted population per PCG (under or over the mean for
that LHA) as stratifying factor. Pharmacists will be ran-
domised along with the PCGs since the meeting scheme
(which pharmacist meeting which PCG) will be defined
before randomisation: this in order to avoid a 'topic-
based' self-selection of visiting pharmacists, which may
introduce a bias (doctors receiving intervention A could
meet more or less motivated pharmacists, than those
receiving intervention B).
About one pharmacist every 8–10 PCGs will get ad hoc
training for the study, getting:
￿ one four-day intensive course (36 hours) on EBM meth-
odology
￿ one three-day course (about 20–22 hours) for each of
the four selected topics, discussing about the benefits and
risks of drugs used in the correspondent clinical area and
their relevance to clinical practice, looking at the available
studies and at their internal/external validity.
Each PCG will nominate a "referent" GP to support phar-
macists during the information meetings. Referents will
get a half-day training module each round on the topic
their group has been randomised to.
Sardinia study (randomising single GPs)
A three-arm RCT is planned: single GPs will be ran-
domised so that they may receive: an outreach visit from
a trained pharmacist, supported by information material
in a 'traditional' format as background material; the same
kind of visit supported by an 'enriched' format (the type
of bulletin used in the cluster study) [17]; or no visit at all
(Fig. 2). Both the effectiveness of the outreach visit and of
the information format will be evaluated (see outcomes).
Two rounds of visits are planned in this study too, each
focusing on one topic. Therefore, only two topics will be
addressed overall (comparing to four used for the other
study). The first topic chosen is 'drugs for the treatment of
benign prostatic hyperplasia'.
The 'traditional' material for this round has been selected
considering its availability and diffusion and its recog-
nised dependability. Two articles on that topic available
in other drug bulletins have been eventually translated
into Italian to be used for this scope: they appeared on the
issue n. 252 of La Revue Prescrire ® and on the issue n. 58
of Therapeutics Letter ® About one pharmacist every 80
Design of the single doctor study (Sardinia): effectiveness of outreach visits and of two different formats Figure 2





with “new” format 
(300)
Outreach visits
with “traditional” format 
(300)
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GPs will receive the same training as the pharmacists in
the other study.
A graphical display of study design is shown in fig. 1 (clus-
ter RCT) and fig. 2.
Outcomes
Main outcome
difference (%) in NHS prescription of drugs under scru-
tiny (expressed as DDD per thousand inhabitants/day),
comparing those who have/do not have received the spe-
cific information. In case of relevant baseline unbalances,
statistical adjustment will be sought
Secondary outcomes
￿ difference in the % of patients who were prescribed the
specific drug(s)
￿ difference in the % of patients who were prescribed the
specific drug(s) for the first time (in the previous 12
months)
￿ difference in expenditure for the specific drug (per 1000
patients/day)
￿ difference in NHS prescription of drugs under scrutiny
(expressed as DDD per thousand inhabitants/day), com-
paring those who have received the "traditional" vs
"enriched" format, and any information vs no informa-
tion (Sardinia study only)
￿ differences in the main and secondary outcomes in each
of the regions involved (cluster study only);
￿ differences in the main and secondary outcomes accord-
ing to the n. of assisted population in the related PCG
(cluster study only)
￿ differences in the main and secondary outcomes accord-
ing to the terziles of physicians age
￿ adjusted difference in prescribed DDD per 1000
patients/day according to a statistical model, considering
as possible covariates: overall prescription in DDD per
1000 patients day at baseline; n. of physicians in the spe-
cific PCGs; n. of assisted population; region (Emilia-
Romagna or Friuli Venezia Giulia); geographical location
(mountain, hill, plain, urban centre – according to defini-
tions given by the Italian Statistics Institute); age distribu-
tion of assisted population (in quartiles); % females in the
assisted population; physician age; total physician drug
expenditure (excluding drugs under scrutiny); % assisted
population with polyprescription (≥ three drugs of differ-
ent classes); n. new prescriptions (in the last 12 months);
month of evaluation; participation to the information
meetings; % exact answers to the questionnaire testing
knowledge (see additional file 1);
￿ difference in the variability (expressed as standard devi-
ations) of prescription of drugs under scrutiny within
PCGs (cluster study only)
￿ difference in knowledge (measured through the n. of
correct answers to a specific anonymous questionnaire,
see additional file)
￿ difference in attitudes (measured through the answers to
a specific questionnaire, see additional file)
Drugs whose NHS prescription will be considered for the
first two topic chosen are specified here below:
1. for benign prostatic hyperplasia, the main indicators
will be: difference in the prescription of 5 alpha-reductase
inhibitors (finasteride and dutasteride, for which a reduc-
tion is expected); and difference in the ratio between the
prescription of alpha blockers terazosin plus tamsulosin
(already off patent drugs) versus other drugs of the same
classes available in Italy (alfuzosin plus doxazosin – an
increase of this ratio is expected). Secondary indicators
will be: difference in the prescription of each of the alpha
blockers listed above (a reduction is expected); difference
of concomitant prescription of 5 alpha-reductase inhibi-
tors and alpha blockers; and overall difference in expend-
iture for either 5 alpha-reductase inhibitors or alpha
blockers (a reduction is expected for both of these indica-
tors).
2. for the primary prevention of osteoporotic fractures, the
main indicators will be: difference in the prescription of
either alendronic acid or of sodium risedronate (a reduced
increase is expected for both of these indicators, especially
for the latter – for which the generic form is still unavaila-
ble). Secondary indicators will be: difference in the pre-
scription of raloxifene and strontium ranelate (a
reduction is expected for both of these indicators); and
difference in the ratio between the prescription of alen-
dronic acid (already off patent) versus the other two oral
bisphosphonates available in Italy (sodium risedronate
and ibandronic acid – an increase of this ratio is expected)
Physicians' expectations, perceived barriers and the added
value about the proposed intervention will be eventually
evaluated through focus groups with a sample of partici-
pating doctors for each region (at the end of the spring
and the autumn rounds).
Economic analysis
If information meetings with small groups of physicians
(Emilia-Romagna and Friuli Venezia Giulia study) or withBMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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single physicians (Sardinia study) will be more effective
than no meetings, we will conduct economic evaluations
for each study to evaluate the opportunity cost of our
interventions.
We will adopt the perspective of the National Health Serv-
ice, not considering indirect costs [18]. As we expect no
health consequences of the changes in prescribing pat-
terns, we will conduct a cost-minimisation analysis evalu-
ating whether the savings on drug-costs are greater than
the costs of the intervention.
In the Emilia-Romagna and Friuli Venezia Giulia study we will
consider the cost of the evidence based bulletins specifi-
cally developed. In the Sardinia study we will consider both
the cost of the evidence based bulletins specifically devel-
oped and the cost of the translation of the articles used as
"traditional" information material.
All costs will be reported in monetary as well as natural
units. An overview of all included costs and data sources
is presented in Table 1. As all costs occur within the same
year, we will not apply discounting.
We will perform a sensitivity analysis, considering how
variations of different parameters can affect results. Specif-
ically, on the cost side we will consider different values in
both quantities and prices of the consumed resources. On
the effectiveness side, we will consider the boundaries of
the confidence intervals. Moreover, we will perform best
case/worst case analysis considering incremental values
for cost and effectiveness (lower costs and better effective-
ness vs higher costs and lower effectiveness).
Follow-up
The follow-up time will be six months after each interven-
tion. A further evaluation will be carried out after 12
months to assess persistence
Information retrieval
Monthly prescription data will be retrieved from provin-
cial drug prescription databases. Although impossible to
eliminate completely, information bias due to database
accuracy should not affect our evaluation significantly,
since limited error rates are expected.
In the cluster RCT, knowledge and attitudes of physicians
will be evaluated through separate questionnaires distrib-
uted during the information meetings. Each set of ques-
tions will be topic dependent, therefore questionnaires
will be developed for each topic. The additional file shows
the questionnaires related to the first two topics.
The knowledge questionnaire will be 'nominal' and filling
up it will be necessary for receiving CME credits, while the
attitude questionnaire will be anonymous so that
responders can express their views freely.
Monitoring of the study
After each meeting, pharmacists will report basic informa-
tion (n. of participating physicians, duration, critical
questions, active participation of 'referents', active partici-
pation to discussion, n. returned questionnaires, etc) on
an online database. The coordinating centre (CeVEAS)
will check that meetings are carried out according to ran-
domisation by monitoring the database, showing up to
about 10% of the meetings at random (for the cluster
study) and contacting physicians by phone (for the Sar-
dinia study)
Sample size estimates
Emilia-Romagna and Friuli Venezia Giulia study (cluster RCT)
From a sample of 40 clusters (about 600 physicians) and
using a dedicated software (Cluster Randomisation Sam-
ple Size Calculator version 1.0.2, Health Services Research
Unit, Aberdeen University) we estimated the intracluster
correlation coefficients (ICC) and the sample size that
Table 1: Input variables in the economic analysis
Variable Data-source (natural units) Source for monetary units
Cost for development of evidence based material and 
translation of drug bulletin
Time spent Salary payments
Training of outreach pharmacists Time spent Salary payments
Training of 'referents' (physicians indicated by each 
PGC)
Time spent Salary payments
Printed materials Invoices Invoices
Travels costs Estimate of distance to practices Travel invoices
Cost of pharmacists doing outreach and making 
appointments
Record of number of visits and days spent on visits Salary payments
Cost of other administrative tasks Estimated time expenditure Salary payments
Cost of physician time Record of length of outreach visit and number of 
physicians
Salary payments
Development of software Invoices, estimates of time spent Invoices, salary payments
Drug expenditure Medical records of prescribing Italian Agency for Drug 2006BMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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would be required to see a difference of 10% in the pre-
scription of a number of possible drugs (15% for bisphos-
phonates), assuming an average cluster (PCG) size of 15
(Table 2).
Since we expect to recruit about 150 PCGs we choose for
the first round of information meetings the two topics
previously described ('drugs for the treatment of benign
prostatic hyperplasia', and 'drugs for the primary preven-
tion of osteoporotic fractures in elderly people') because
of the clinical relevance of the information to be pre-
sented.
Sardinia study (randomising single GPs)
We expect to recruit about 900 General Practitioners. Such
a sample would exceed the number needed to assess the
same objectives described for the other study.
Statistical analysis
The statistical analysis will be performed according to the
intention-to-treat principle, analysing physicians' pre-
scriptions according to the treatment group to which they
were randomly allocated (as single GPs or as members of
PCGs), and independently from their participation to the
outreach visits. A 'modified intention to treat' will be con-
sidered in case some physician should not be actually
offered the randomised intervention (for example, if
pharmacists should become unavailable in a given area
for organisational reasons or if health policy issues should
arise, e.g. lack of agreement with medical syndicates, etc).
Secondly, a by treatment analysis will also be performed
considering only physicians who actually participated to
the visits.
T-test (for continuing variables), chi-square test (for dis-
crete variables) and multiple linear regression will be
used, the latter to investigate how specific variables (like
baseline prescriptions, region, size of PCG, size of assisted
population, age and sex of GP, month of follow-up, etc)
can affect outcomes. Analysis of covariance (ANCOVA)
will be used for evaluating primary outcomes in case rele-
vant baseline imbalances (for example in the prescription
of targeted drugs) will make statistical adjustment neces-
sary.
Organizational characteristics
CeVEAS will coordinate and monitor all the aspects of the
study and will be in close connection with the Health
Table 2: Estimates of sample sizes to detect a prescribing difference of 10% (with two-tailed test)
ATC code Estimate of ICC Sample size (NCP)
macrolides J01FA 0.024 68
fluoroquinolones J01MA 0.030 68
antidepressants n06ab 0.058 88
nitroderivatives C01da02, 05,08,14 0.09 96
bifosphosphonates (15% diff) M05ba 0.062 106
proton pump inhibitors A02BC 0.087 108
phosphomicine J01xx01 0.014 108
Alfa blockers (for IPB) g04ca + g04bx49 0.075 116
doxazosin (for IPB) c02ca04 0.038 128
long acting β2 broncodilators + corticosteroids R03AK06 e R03AK07 0.092 148
Finasteride +dutasteride g04cb 0.08 154
opioids N02A 0.061 164
clarithromicine J01fa09 0.02 172
esomeprazole A02bc05 0.023 204
long acting β2 broncodilators R03AC12 e R03AC13 0.033 208
alendronate M05ba04 0.08 218
finasteride g04cb01 0.1 220
salmeterol + corticosteroids R03ak06 0.102 234
bifosphosphonates M05ba 0.062 238
azitromicine J01fa10 0.068 266
risedronate M05ba07 0 374
norfloxacine J01ma06 0.055 386
fentanyl N02ab03 0.043 428
salmeterol R03ac12 0.053 698
morphine N02aa01 0.05 2224
buprenorphine N02ae01 0 Nc
bicalutamide l02bb03 0 Nc
escitalopram N06ab10 0 1434
levocetirizine R06ae09 0.032 >600
antiandrogens L02bb01+ L02bb03 0 ncBMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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Authorities in charge of the local organization. CeVEAS
will also provide the necessary training to the pharmacists
involved, and will carry out the final evaluation of the
study. Regional Health Authorities of Emilia-Romagna,
Friuli Venezia Giulia and Sardinia will help select the
Local Health Authorities where the study will be carried
out, and will participate to the local organization of the
project. Local Health Authorities (LHAs) will ensure the
local organization, selecting "outreach" pharmacists, pro-
moting their training, and promoting and scheduling the
outreach visits. LHAs will also ensure the retrieval of drug
prescribing data for the entire study period. Regional and
Local Health Authorities do not need previous experience
in setting outreach visits programs, the only requirement
being the availability of reliable drug prescription data-
bases for retrieval of GPs' prescribing data.
Steering Committee
A Steering Committee (SC) was nominated in September
2006 to approve the final version of the protocol and to
address ethical matters. Specifically, the SC will supervise
study organisation, conduct and analysis of results, and
will be made of 16 components: a chairman; three repre-
sentatives of the coordinating centre; one representative of
the Regional Health Authority, two representatives of GPs
and one representative of pharmacists for each of the
three participating regions. Specifically the SC will:
￿ verify that all the Health Authorities involved adhere to
the minimum requirements indicated in the study proto-
col, in keeping with the pragmatic nature of the study
￿ verify that data have been adequately checked for quality
￿ supervise the production of reports to inform the partic-
ipating Health Authorities about the progression of the
study
￿ monitor the scientific literature to seek for possibile new
relevant information on the discussed topics
￿ evaluate possible amendments to the protocol
Discussion
The two proposed RCTs will let us better understand the
potential usefulness of NHS pharmacists assuming a more
active role in transferring evidence-based information to
physicians. Besides data on prescribing impact, the studies
will provide qualitative insight on the feasibility of such
information programs, with special attention to how dif-
ferent organizational settings in different regional areas
may lead to better or worse implementation. As already
said, these studies represent an unprecedented effort to
accomplish such evaluations on quite a large scale and in
a 'natural' organizational setting, which would be mini-
mally altered by the interventions themselves. Moreover,
the two RCTs will test two different strategies of informa-
tion delivery: using small groups or one to one meetings.
While these strategies will not be directly compared
(being not employed in the same study but in two differ-
ent ones), their feasibility and impact will be critically
evaluated, also in light of other experiences described in
the scientific literature and of methods used by the phar-
maceutical industry to bring information to doctors on a
large scale.
Last but not the least, the role of the format of medical
information will be investigated: this could be a critical
part in the implementation of information programs and
its importance may be often underestimated, considering
that medical schools generally do not offer the necessary
tools to unscramble data published in the scientific litera-
ture; that average doctors do not have enough time to
select and read what may add relevant information to
their knowledge; and that, eventually, the uptake of this
information may be facilitated by offering it in a clear,
direct and appealing fashion, looking at the context of
clinical practice [17].
As usually happens, the evaluation of complex interven-
tions is intricate given the many different variables into
play: it is the other side of the pragmatic nature of these
RCTs, which is also, and undoubtedly, one of their
strengths. Moreover, the ambitious quantitative hypothe-
sis to be tested (10 or 15% difference in doctors' prescrip-
tions) will not be easily demonstrated, in spite of the
involvement of about 2000 physicians in the cluster RCT
and about 900 in the single doctors RCT: an even larger
sample size would have been necessary to see smaller but
still relevant prescribing differences.
Feasibility
The Centre for the Evaluation of the Effectiveness of
Health Care (CeVEAS), a NHS Centre dedicated to the
production and implementation of independent informa-
tion, has already been implementing outreach visit pro-
grams in selected areas of Emilia-Romagna starting from
2001, using "Information Packages on Drugs" ® (drug
information bulletins, registered in the International Soci-
ety of Drug Bulletins since 2006, developed to facilitate
knowledge transfer). However, the large scale feasibility of
such information program has not been formally tested,
neither a formal impact assessment on physicians' knowl-
edge, attitudes and prescribing practice has been carried
out.
Ethical aspects
Between November 2006 and March 2007, the protocol
was sent to the Local Ethics Committees (LEC) of the
Health Authorities involved. Most of the LEC have alreadyBMC Health Services Research 2007, 7:158 http://www.biomedcentral.com/1472-6963/7/158
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approved the protocol, some specifying that it was unnec-
essary to analyse it formally since no ethical problems
arise in carrying out a randomisation differentiating the
kind of information actively discussed during the out-
reach visits. In any case, the same information will be
available to everybody outside the study meetings. At the
end of each follow-up period, the information discussed
during outreach visits will be proactively sent to each phy-
sician unexposed to that specific information during the
outreach visits.
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